Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitations

Michael Hardy, Jonathan Douxfils, Marion Bareille, Sarah Lessire, Isabelle Gouin-Thibault, Pierre Fontana, Thomas Lecompte, François Mullier

Résultats de recherche: Contribution à un journal/une revueLettreRevue par des pairs

1 Téléchargements (Pure)

Résumé

We read with much interest the recent observational study of Nougier et al., which aimed at studying thrombin generation (TG) and fibrinolysis profiles of COVID-19 patients admitted to an intensive care unit (ICU) or to an internal medicine ward and receiving various schemes of prophylactic heparin.[1] They reported that thrombin potential remained within normal range despite heparin and that fibrinolysis was decreased in relation with increased plasminogen activator inhibitor 1 (PAI-1) and thrombin-activatable fibrinolysis inhibitor (TAFI) antigen plasma levels. Using the rotational thromboelastometry (ROTEM) delta device with EXTEM reagents and the addition of 0.625µg/mL tPA (referred to as 'TEM-tPA'), they reported decreased clot lysis in COVID-19 patients, which was more pronounced in patients who presented a thrombotic event, compared to event-free patients.

langue originaleAnglais
journalJournal of thrombosis and haemostasis : JTH
Date de mise en ligne précoce2020
Les DOIs
Etat de la publicationPublié - 2020

Empreinte digitale Examiner les sujets de recherche de « Studies on hemostasis in COVID-19 deserve careful reporting of the laboratory methods, their significance and their limitations ». Ensemble, ils forment une empreinte digitale unique.

Contient cette citation